Adalimumab compared with mycophenolate mofetil for steroid-dependent non-infectious uveitis
Compares adalimumab with mycophenolate mofetil in adults with steroid-dependent non-infectious uveitis.
Key facts
- Who runs it
- Assistance Publique Hopitaux De Paris
- Where
- France28 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- “Randomized controlled multicenter study comparing efficacy and safety of adalimumab to that of mycophenolate mofetil in steroid dependent non-infectious uveitis” - FOCUS
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 120 people, planned
- Started
- 1 Jul 2024
- Expected to end
- 1 Jun 2027
- Type of study
- Interventional
- Record updated
- 22 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-infectious uveitis (eye inflammation) at the middle, back or whole of the eye. Their disease must still be active despite steroid tablets. It compares adalimumab with mycophenolate mofetil.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Non-infectious intermediate, posterior or pan-uveitis in at least one eye, by SUN criteria. Signs of activity in the 3 months before joining, such as active retina lesions, macular edema, or ≥ 2+ cells or haze in the eye.
- Earlier treatment
- Disease active despite >7mg/day of oral prednisone. No systemic alkylating agents (e.g., cyclophosphamide, chlorambucil) within 12 months. No live vaccine within 4 weeks. People with latent TB must agree to take TB preventive treatment if not already done.
- Biomarker or test result
- Chest X-ray or CT scan within 12 weeks with no active tuberculosis, infection or cancer. A positive IGRA test is allowed if there is no active TB. Women who could become pregnant need a negative pregnancy test.
Main reasons for not taking part
- Infectious uveitis, masquerade syndromes, or uveitis only at the front of the eye
- Only one seeing eye, active tuberculosis, or positive HIV, HCV or HBs Ag test
- Cancer within 5 years, except some skin cancers or cervical carcinoma in situ
- Heart failure NYHA stage III or IV, multiple sclerosis or demyelinating disorder
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- The eligibility criteria will be checked at the screening visit (which takes place four weeks maximum prior to inclusion visit) and at the inclusion/randomization visit. Adult patients meeting the following criteria may be included in the study: 1. Provide written, informed consent prior to the performance of any study specific procedures
- ≥18 years of age
- Diagnosis of non-infectious intermediate, posterior-, or pan-uveitis in at least one eye fulfilling the International Study Group Classification Criteria (Standardization of Uveitis Nomenclature [SUN] criteria) of intermediate, posterior, or pan- uveitis confirmed by documented medical history
- Recent activity of NIU as defined by the presence of at least 1 of the following parameters in either eye within the 3 months prior to inclusion visit despite >7mg/day of oral prednisone: a) Active chorioretinal or retinal vascular lesion b) Presence of macular edema by optical coherence. c) ≥ 2+ anterior chamber cells (Standardization of Uveitis Nomenclature [SUN] criteria) d) ≥ 2+ vitreous haze (National Eye Institute [NEI]/SUN criteria)
- Chest X-ray or CT-scanner results within 12 weeks prior to inclusion with no evidence of active Tuberculosis, active infection, or malignancy
- A potential subject with a positive interferon-gamma release assay (IGRA) (e.g., QuantiFERON®-TB Gold or T-spot TB® Test) obtained within 12 weeks prior to inclusion is eligible if: a. Her/his chest X-ray does not show evidence suggestive of active TB disease b. And there are no clinical signs and symptoms of pulmonary and/or extra-pulmonary TB disease. c. And these subjects with a latent TB infection who have not already received a prophylactic TB treatment must agree in advance to complete such a treatment course
- For female subjects of child-bearing potential: a negative pregnancy test at inclusion
- For subjects with reproductive potential, a willingness to use contraceptive measures adequate to prevent the subject or the subject’s partner from becoming pregnant during the study and 3 months and 5 months after stopping therapy for MMF and adalimumab, respectively, unless sterility is confirmed. The simultaneous use of two complementary methods of contraception is preferable. Methods which may be considered as highly effective methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods (according to CTFG recommendations). Such methods include: For Female subjects : a. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation 1: ▪ oral ▪ intravaginal ▪ transdermal b. progestogen-only hormonal contraception associated with inhibition of ovulation: ▪ oral ▪ injectable ▪ implantable c. intrauterine device (IUD) d. intrauterine hormone-releasing system (IUS) e. bilateral tubal occlusion f. vasectomised partner g. sexual abstinence (In the context of this guidance sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject). For male subjects : a. use of condoms b. vasectomy (with documentation of azoospermia) c. sexual abstinence
- Affiliated to a social security system
Who cannot take part
- Use of the following systemic treatments during the specified periods: • Treatment with any systemic alkylating agents within 12 months prior to inclusion (e.g., cyclophosphamide, chlorambucil) • Any live (attenuated) vaccine within 4 weeks prior to inclusion
- Participation in another interventional study involving human participants or in the exclusion period at the end of a previous study involving human participants, if applicable
- Infection requiring treatment with intravenous antibiotics within 3 weeks prior to inclusion
- Subjects will not be included in the study if they meet any of the following criteria: 1. Infectious uveitis, masquerade syndromes (idiopathic uveitis is permitted)
- Stage III and IV New York Heart Association (NYHA) cardiac insufficiency
- Active tuberculosis
- Positive HIV serology or HCV HBs Ag test
- History of malignancy within 5 years prior to Inclusion other than carcinoma in situ of the cervix, non-metastatic squamous or basal cell carcinoma of the skin
- History of severe allergic or anaphylactic reactions to monoclonal antibodies, mycophenolate mofetil, rifampicin, isoniazid or fluorescein
- History of multiple sclerosis and/or demyelinating disorder
- Laboratory values assessed during inclusion: • Hemoglobin < 8g/dL • WBC < 2.0 x 103/mm3 • Platelet count < 80 x 103/mm3 • Glomerular filtration rates (GFR) <30ml/min. • Transaminases > 3 times upper normal value
- Pregnancy or breastfeeding
- Under legal protection
- Isolated anterior uveitis
- Monophtalmic patient
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The objective is to compare the efficacy of adalimumab (80mg at day 0, then 40mg/14 days from W1 to W35 subcutaneously) with that of standard of care (mycophenolate mofetil [2g/day orally] for 36 weeks) in recently active non-infectious intermediate, posterior uveitis, and pan-uveitis with steroid dependency.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Randomized controlled multicenter study comparing efficacy and safety of adalimumab to that of mycophenolate mofetil in steroid dependent non-infectious uveitis. FOCUS: treatment FOr Corticosteroid dependent UveitiS
- Plain-language title
- Adalimumab compared with mycophenolate mofetil for steroid-dependent non-infectious uveitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 22 April 2025